NCT07106814View on ClinicalTrials.gov

Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

August 15, 2027

Study Completion Date

December 30, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

Metabolically Armed TIL cells

Each subject receive metabolically armed TIL cells by intravenous infusion.

Trial Locations (1)

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei

Sponsors

Collaborators (1)

Leman Biotech Co., Ltd.

All Listed Sponsors

collaborator

Leman Biotech Co., Ltd.

INDUSTRY

lead

Anhui Provincial Hospital

OTHER_GOV